GET DAILY SIGNALSBrainsWay Ltd. (BWAY): Can Shares Reach the $19 Analyst Target?
Key Takeaways
- The $19 central target is the arithmetic mean of three verified analyst price targets ($18.80, $19.00, and $20.00), which rounds down from a calculated average of roughly $19.27.
- With shares near $10.60 after a post-earnings decline, reaching $19 implies a gain of roughly 80% — a very large move.
- The verified analyst target range is narrow, from about $18.80 to $20.00, with all three covering firms maintaining Buy ratings.
- Supporting factors include 34% year-over-year revenue growth, a 78% gross margin, an $85 million remaining performance obligation (RPO) backlog, and more than 70 million U.S. covered lives for its SWIFT protocol.
- Key risks include a third-quarter EPS miss, rising operating expenses and share-based compensation, and a still-pending FDA review for comorbid PTSD and major depressive disorder.
- For ongoing coverage, explore Major News, Today's Price Move, the Forecast page, and Earnings data for BrainsWay.
- Traders seeking systematic signals can explore Trending AI Robots for automated, AI-driven market monitoring.
What the Analysts Are Projecting
BrainsWay Ltd. (BWAY) receives limited sell-side attention, so any consensus figure rests on just a few estimates. Three current price targets stand out. H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating with a $19 target in early November 2026, while BTIG's Sam Eiber maintained a Buy with a $20 target in October 2026, and Ladenburg Thalmann held an $18.80 target after the second-quarter report. The arithmetic mean of those three figures comes to about $19.27, which rounds to the $19 central target. The tight range from $18.80 to $20.00 suggests broad agreement on the growth path, driven by accelerating system shipments, expanding reimbursement for the SWIFT protocol, and a growing recurring-revenue base. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how technical conditions align with the fundamental outlook.
Where the Stock Stands Today
Shares closed near $11.64 in early November 2026 but slid to roughly $10.60 after third-quarter results, trading in a 52-week range of about $7.14 to $17.40. Reaching $19 from approximately $10.60 requires a gain of about 80%, a substantial move even for a high-growth small-cap medical device company. The stock would first need to reclaim and exceed its 52-week high of $17.40. In my view, the path hinges on sustained double-digit revenue growth, further margin expansion, and progress on reimbursement and regulatory catalysts rather than any single quarter. BrainsWay shipped 130 Deep TMS systems in the third quarter, up 44% year over year, lifting the installed base past roughly 2,080 systems, and management raised full-year 2026 guidance to the upper end of its prior range with the potential to modestly exceed it.
Factors That Could Support a Move Higher
BrainsWay’s third quarter reflected a fundamentally stronger business despite the headline EPS shortfall. Revenue rose 34% to $18.1 million, gross margin reached 78%, adjusted EBITDA nearly doubled to $3.9 million, and operating cash flow improved to $6.2 million. Remaining performance obligations reached approximately $85 million, up 31%, offering revenue visibility. Reimbursement remains a key driver: more than 70 million U.S. lives now have access to SWIFT protocol coverage, well ahead of the earlier target, and management noted that roughly half of new demand involves SWIFT. A strong cash position of about $63 million and FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction underpin the growth story. From what I see, these elements form the core of the bull case.
Potential Obstacles to Reaching the Target
The most immediate challenge is execution relative to expectations. BrainsWay reported third-quarter EPS of $0.05, missing the roughly $0.09 consensus, as operating expenses rose 29% and share-based compensation more than doubled. Valuation is another factor: with a trailing P/E ratio around 46 and a small market capitalization, the stock can de-rate quickly if growth disappoints. The FDA clearance for comorbid PTSD and major depressive disorder remains under review, and order flow from newer partnerships can be lumpy. As a thinly traded small cap, the stock is also vulnerable to outsized moves on limited news.
Technical Levels to Watch
The $17.40 level, the stock’s 52-week high, represents the most relevant near-term resistance, followed by the psychological $20 round number that aligns with the highest analyst target. On the downside, the post-earnings $10 area and the 52-week low near $7.14 are the notable support zones. A sustained move toward $19 would require the shares to break decisively above the prior 52-week high and hold that level as new support. I’m watching this closely as the technical setup evolves.
Time Horizon and Key Items to Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the three covering firms do not publish identical timing assumptions. Investors should watch quarterly earnings and guidance, system shipment and RPO trends, margin progression, and any update on the PTSD/MDD regulatory review. Reimbursement expansion for SWIFT and OCD coverage, along with analyst target revisions following each quarterly report, are the most likely catalysts.
Using AI Tools in My Research Process
Tickeron’s AI Daily Buy/Sell Signals provide an additional layer of systematic insight for names like BrainsWay. I find these signals helpful for monitoring technical shifts and identifying potential entry or exit points alongside fundamental analysis, especially for a volatile small-cap stock where market conditions can change quickly. This approach adds an objective, data-driven perspective that complements traditional research without replacing it.
Final Assessment
The $19 central target represents a calculated average of three Buy-rated analyst targets, ranging narrowly from $18.80 to $20.00. From a post-earnings price near $10.60, that implies an upside of roughly 80%, which remains a substantial hurdle. The bull case rests on accelerating system placements, a growing recurring-revenue backlog, margin expansion, and reimbursement gains, while the bear case centers on the EPS miss, rising costs, a pending regulatory decision, and a rich valuation for a small-cap device maker. Whether BrainsWay can reach $19 will ultimately depend on whether it sustains its growth and margin trajectory while converting its reimbursement momentum into durable profitability. No analyst target, including this calculated mean, is a guarantee of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BWAY's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BWAY turned positive on October 19, 2026. Looking at past instances where BWAY's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BWAY's RSI Oscillator exited the oversold zone, 16 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 57 cases where BWAY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
Following a +9.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where BWAY advanced for three days, in 219 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
BWAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BWAY as a result. In 82 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BWAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for BWAY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. BWAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BWAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.666) is normal, around the industry mean (4.142). P/E Ratio (44.600) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (8.681) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of deep transcranial magnetic stimluation systems, novel, noninvasive medical devices
Industry MedicalNursingServices
Advertisement